Skip to content

Acupuncture for Treating Coronary Microvascular Dysfunction in Acute Myocardial Infarction: A Randomized Controlled Trial Protocol (ACU-AMI Trial)

Acupuncture for Treating Coronary Microvascular Dysfunction in Acute Myocardial Infarction: A Randomized Controlled Trial Protocol (ACU-AMI Trial)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079603
Enrollment
Unknown
Registered
2024-01-08
Start date
2024-01-10
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stsegment Elevation Myocardial Infarction

Interventions

disease-affected meridian (DAM) group:The DAM group acupoints include CV14 (Juque), CV4 (Guayuan), and bilateral PC6 (Neiguan), L14(Hegu), ST36 (Zusanli), LR 3(Taichong).
non-affected meridian (NAM) group:The NAM group acupoints include bilateral acupoints LU9 (kongzui) and LU6 (Taiyuan)

Sponsors

Heart Center, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) Aged 18-75 years. (2) First medical contact=12 hours. (3) Diagnosis of Anterior STEM: Patients admitted with criteria for anterior STEMI according to the fourth universal definition of myocardial infarction[21]. New ST-elevation at the J-point in 2 contiguous leads with the cut-point: =1 mm in precordial leads other than leads V2–V3 where the following cut-points apply: =2 mm in men =40 years; =2.5 mm in men 90U (6) Consent to participate.

Exclusion criteria

Exclusion criteria: (1) Prior angina pectoris, myocardial infaction, or revascularization (PCI or CABG) (2) Severe cardiac insufficiency or hypotension (systolic blood pressure 3-fold ULN; eGFR<30ml/min/1.73mm2) (6) Patients with end-stage diseases (such as untreatable malignancies) and a life expectancy of less than 1 year (7) Pregnancy, lactation, or potentially fertile women (8) Allergy to any medication used in hospital (9) Participating in other interventional clinical trial or the investigator considers it inappropriate to participate in this study

Design outcomes

Primary

MeasureTime frame
CK-MB;Area under the curve (AUC) of serum CK-MB release;

Secondary

MeasureTime frame
ST segment resolution;Myocardial flow reserve;cardiac functional parameters (left ventricular ejection fractions, speckle tracking, longitudinal strain);inflammatory factors (IL-6, hs-CRP, and TNF-a);markers of endothelial injury (ET-1, vWF, and P-selectin);Major adverse cardiovascular events within 6 months;Questionnaire of quality of life:;any adverse events;serious adverse events;

Countries

China

Contacts

Public ContactXiaowei Niu

First Hospital of Lanzhou University

husw2022@qq.com+86 931 835 6955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026